Sign in

NCT04467333Recruiting

Giessen Pulmonary Hypertension in Lung Cancer Registry

Source: ClinicalTrials.gov · Last updated 1 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity in lung cancer patients. All information will be generated from the regular guidelines based course of treatment and there will be no interventions. This study will serve as a prospective register for all lung cancer patients treated at the university hospital Giessen.

Status (registry)
Recruiting
Study type
Observational
Enrollment
500 (estimated)
First submitted
1 Jul 2020
Start date
29 Jun 2020
Primary completion date
29 Jan 2026
Lead sponsor
University of Giessen
NCT number
NCT04467333

What you commit to

  • Study type: Observational
  • Planned participants: 500
  • From 29 Jun 2020 to the primary completion date, 29 Jan 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • \-

Who the study is looking for

  • Patient with lung cancer at the University of Giessen lung Cancer Center.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University hospital Giessen
Coordinator of this site? Confirm its status
GiessenGermanyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.